Monoclonal Anti-Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein, Clone 2B11 (produced *in vitro*)

Catalog No. NR-40257

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

Connie S. Schmaljohn, Ph.D., Chief Scientist, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Manufacturer:

BEI Resources

Product Description:

Antibody Class: IgG1κ

Mouse monoclonal antibody prepared against the Crimean-Congo hemorrhagic fever virus (CCHFV) nucleocapsid protein was purified from clone 2B11 hybridoma supernatant using protein G affinity chromatography. The B cell hybridoma was generated by the fusion of Sp2/0-Ag14 mouse myeloma cells with splenocytes from BALB/c mice immunized with CCHFV-infected suckling mouse brain homogenates as described by Bertolotti-Ciarlet et al.[1,2]

This reagent is part of the Joel M. Dalrymple – Clarence J. Peters USAMRIID Antibody Collection.

Material Provided:

Each vial of NR-40257 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-40257 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-40257 is reactive in indirect immunofluorescence assays using Vero E6 cells infected with CCHFV. The antibody is not neutralizing *in vitro*. Clone 2B11 antibody is also reported to function in ELISA.[1,2,3]

Citation:

Acknowledgment for publications should read "The following reagent was obtained from the Joel M. Dalrymple – Clarence J. Peters USAMRIID Antibody Collection through BEI Resources, NIAID, NIH: Monoclonal Anti-Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein, Clone 2B11 (produced *in vitro*), NR-40257."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Bertolotti-Ciarlet, A., et al. "Cellular Localization and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus Glycoproteins." J. Virol. 79 (2005): 6152-6161. PubMed: 15858000.
2. Ahmed, A. A., et al. "Presence of Broadly Reactive and Group-Specific Neutralizing Epitopes on Newly Described

Isolates of Crimean-Congo Hemorrhagic Fever Virus." J. Gen. Virol. 86 (2005): 3327-3336. PubMed: 16298978.
3. Schmaljohn, C. S., Personal Communication.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898